The proteasome: A target novel for cancer chemotherapy

Leukemia

Volumn 16, Issue 4, 2002, Pages 433-443

  Almond, J B ^a   Cohen, G M ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Apoptosis; Cancer; Proteasome; Proteasome inhibitors

Indexed keywords

ANTINEOPLASTIC AGENT; CYSTEINE PROTEINASE; ENZYME INHIBITOR; MULTIENZYME COMPLEX; PROTEASOME; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; CASPASE 3; CASPASE 7; CASPASE 9; CEP 1612; CYTOCHROME C; EPONOMYCIN; GENE PRODUCT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LACTACYSTIN; MG 115; MYC PROTEIN; PROTEASOME INHIBITOR; PROTEIN BCL 2; PROTEIN P27; PROTEIN P53; STRESS ACTIVATED PROTEIN KINASE; UBIQUITIN; UNCLASSIFIED DRUG;

ANIMAL; APOPTOSIS; DRUG ANTAGONISM; ENZYMOLOGY; HUMAN; NEOPLASM; REVIEW; ANGIOGENESIS; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; BIOCHEMISTRY; CANCER CELL; CANCER CHEMOTHERAPY; CELL GROWTH; CELL PROLIFERATION; CELL STRUCTURE; CELL TRANSFORMATION; CELL TYPE; CYTOTOXICITY; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVATION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GROWTH INHIBITION; GROWTH REGULATION; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL; METASTASIS INHIBITION; MITOCHONDRION; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN FAMILY; RAT; SENSITIVITY ANALYSIS; TRANSCRIPTION REGULATION; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CYSTEINE ENDOPEPTIDASES; ENZYME INHIBITORS; HUMANS; MULTIENZYME COMPLEXES; NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX;

EID: 0036240701     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402417     Document Type: Review

References (86)

1. The ubiquitin-proteasome proteolytic pathway
2. Subcellular localization of proteasomes and their regulatory complexes in mammalian cells
3. The proteasome: A macromolecular assembly designed to confine proteolysis to a nanocompartment
4. Self-compartmentalizing proteases
5. The proteasome: Paradigm of a self-compartmentalizing protease
6. The ubiquitin system
7. The ubiquitin system
8. Proteasome inhibitors as anti-cancer agents
9. Roles of ubiquitin-mediated proteolysis in cell cycle control
10. How proteolysis drives the cell cycle
11. Role of proteasomes in T cell activation and proliferation
12. The role of the ubiquitin-proteasome pathway in apoptosis
13. The ubiquitin-proteasome pathway in cancer
14. Phosphorylation meets ubiquitination: The control of NF-κB activity
15. Recent advances in understanding proteasome function
16. Protein complexes activate distinct caspase cascades in death receptor and stress-induced apoptosis
17. Apaf-1 oligomerizes into biologically active ∼700-kDa and inactive ∼ 1.4-MDa apoptosome complexes
18. Caspases: The executioners of apoptosis
19. Mammalian caspases: Structure, activation, substrates, and functions during apoptosis
20. Caspase structure, proteolytic substrates, and function during apoptotic cell death
21. The inhibitor of apoptosis, cIAP2, functions as a ubiquitin-protein ligase and promotes in vitro monoubiquitination of caspases 3 and 7
22. mdm2 and bax, downstream mediators of the p53 response, are degraded by the ubiquitin-proteasome pathway
23. Ubiquitin-mediated degradation of the proapoptotic active form of bid: A functional consequence on apoptosis induction
24. Bax degradation by the ubiquitin/proteasome-dependent pathway: Involvement in tumor survival and progression
25. Proteasomes modulate balance among proapoptotic and antiapoptotic Bcl-2 family members and compromise functioning of the electron transport chain in leukemic cells
26. Proteasome inhibitors: Valuable new tools for cell biologists
27. Proteasome inhibition: A new strategy in cancer treatment
28. Mechanistic studies on the inactivation of the proteasome by lactacystin: A central role for clasto-lactacystin beta-lactone
29. Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin
30. Lactacystin, proteasome function, and cell fate
31. Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids
32. Characterization of peptidyl boronic acid inhibitors of mammalian 20 S and 26 S proteasomes and their inhibition of proteasome in cultured cells
33. Activation of the cell death program by inhibition of proteasome function
34. Proteasome inhibitor-induced apoptosis of B-chronic lymphocytic leukaemia cells involves cytochrome c release and caspase activation, accompanied by formation of an ∼700 kDa Apaf-1 containing apoptosome complex
35. The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-α-initiated apoptosis
36. Increased sensitivity of CLL-derived lymphocytes to apoptotic death activation by the proteasome-specific inhibitor lactacystin
37. Deregulation of the ubiquitin system and p53 proteolysis modify the apoptotic response in B-CLL lymphocytes
38. Ubiquitin-proteasome system and increased sensitivity of B-CLL lymphocytes to apoptotic death activation
39. Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukemic lymphocytes
40. Proteasome inhibitors: A novel class of potent and effective antitumor agents
41. Proteasome activation occurs at an early, premitochondrial step of thymocyte apoptosis
42. Inhibition of etoposide-induced apoptosis with peptide aldehyde inhibitors of proteasome
43. Proteasomes play an essential role in thymocyte apoptosis
44. Involvement of the proteasome in the programmed cell death of NGF-deprived sympathetic neurons
45. Prevention of etoposide-induced apoptosis by proteasome inhibitors in a human leukemic cell line but not in fresh acute leukemia blasts: A differential role of NF-κ B activation
46. Proteasome inhibitors activate stress kinases and induce Hsp72. Diverse effects on apoptosis
47. p53 mutations in human cancers
48. In vivo ubiquitination and proteasome-mediated degradation of p53
49. Apoptotic death sensor: An organelle's alter ego?
50. Surfing the p53 network
51. p53-dependent induction of apoptosis by proteasome inhibitors
52. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts
53. Prostate carcinoma cell death resulting from inhibition of proteasome activity is independent of functional Bcl-2 and p53
54. Proteasome inhibition leads to significant reduction of Bcr-Abl expression and subsequent induction of apoptosis in K562 human chronic myelogenous leukemia cells
55. Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells
56. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27
57. kipl: A multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers
58. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor
59. JNK (c-Jun N-terminal kinase) and p38 activation in receptor-mediated and chemically-induced apoptosis of T-cells: Differential requirements for caspase activation
60. Diverse functions of JNK signaling and c-Jun in stress response and apoptosis
61. L in response to DNA damage
62. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway
63. Suppression of tumor necrosis factor-induced cell death by inhibitor of apoptosis c-lAP2 is under NF-κB control
64. ch-IAP1, a member of the inhibitor-of-apoptosis protein family, is a mediator of the antiapoptotic activity of the v-Rel oncoprotein
65. NF-κB antiapoptosis: Induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation
66. The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF- κB that blocks TNFα-induced apoptosis
67. Rel-dependent induction of A1 transcription is required to protect B cells from antigen receptor ligation-induced apoptosis
68. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: Implications for systemic nuclear factor-κB inhibition
69. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-κB, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma
70. The proteasome is involved in angiogenesis
71. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells
72. Proteasome inhibitors as potential novel anticancer agents
73. Resistance to diverse drugs and ultraviolet light conferred by overexpression of a novel human 26 S proteasome subunit
74. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade
75. Caspase activation involves the formation of the aposome, a large (∼700 kDa) caspase-activating complex
76. Recruitment, activation and retention of caspases-9 and -3 by Apaf-1 apoptosome and associated XIAP complexes
77. The proteasome inhibitor PS-341 in cancer therapy
78. KIP1 expression and apoptosis and inhibits the growth of the human lung adenocarcinoma A-549 in nude mice
79. An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses
80. Proteasomes are a target of the anti-tumour drug vinblastine
81. Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition
82. Eponemycin analogues: Syntheses and use as probes of angiogenesis
83. Lactacystin, a specific inhibitor of the proteasome, induces apoptopsis in human monoblast U937 cells
84. Apoptosis induction resulting from proteasome inhibition
85. Inhibition of proteasome function prevents thymocyte apoptosis: Involvement of ornithine decarboxylase
86. Inhibition versus induction of apoptosis by proteasome inhibitors depends on concentration